Approach

Summary

Licensing status

Publication and contact information

Disease models

Patient induced pluripotent stem (iPS) cell-derived cardiomyocytes as models for right ventricular dysplasia/cardiomyopathy

Cardiomyocytes generated from patient-derived iPS cells could help identify new treatments for right ventricular dysplasia/cardiomyopathy. Fibroblasts were isolated from an adult patient, reprogrammed into iPS cells and subsequently differentiated into cardiomyocytes. In culture, the resulting cells recapitulated an adult cardiomyocyte phenotype, showing exaggerated lipogenesis and deficiencies in calcium handling and greater apoptosis than control cells. Next steps include extending the findings to additional subtypes of right ventricular dysplasia/cardiomyopathy and using the patient-derived cells to evaluate therapeutic candidates.

SciBX 6(6); doi:10.1038/scibx.2013.151
Published online Feb. 14, 2013

Patents pending; licensing status undisclosed

Kim, C. et al. Nature; published online Jan. 27, 2013;
doi:10.1038/nature11799
Contact: Huei-Sheng Vincent Chen, Sanford-Burnham Medical Research Institute, La Jolla, Calif.
e-mail:

hsv_chen@burnham.org